Co-Diagnostics
CODX
95 hedge funds and large institutions have $85.7M invested in Co-Diagnostics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
19% more capital invested
Capital invested by funds: $71.9M → $85.7M (+$13.8M)
14% more funds holding
Funds holding: 83 → 95 (+12)
0.13% more ownership
Funds ownership: 0.91% → 1.05% (+0.13%)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
30% less call options, than puts
Call options by funds: $6.82M | Put options by funds: $9.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.88M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$2.67M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.65M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$2.28M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$1.3M |
| 2 |
Barclays
London,
United Kingdom
|
-$1.26M |
| 3 |
Millennium Management
New York
|
-$595K |
| 4 |
Morgan Stanley
New York
|
-$466K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$449K |
CODX Hedge Fund Activity: Q1 2021 in Review
95 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2021, worth a combined $85.7M — up 19% from $71.9M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CODX positions and 12 closed out — a net gain of 12 holders — while 26 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $2.88M. The largest seller was Bank Julius Baer & Co, cutting an estimated $1.3M.
- 95 institutional investors held Co-Diagnostics (CODX) as of Q1 2021, up from 83 in Q4 2020.
- Funds reported $85.7M of Co-Diagnostics stock for Q1 2021, up 19% quarter-over-quarter.
- 24 funds opened new Co-Diagnostics positions in Q1 2021 and 12 closed out, a net change of +12 holders.
- The largest Co-Diagnostics buyer in Q1 2021 was Vanguard Group, an estimated $2.88M added.
- The largest Co-Diagnostics seller in Q1 2021 was Bank Julius Baer & Co, an estimated $1.3M sold.
Based on aggregated 13F filings for Q1 2021.